MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.drugalcdep.2022.109673

Медицинская библиотека · Drug and alcohol dependence · 2022

Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.

Chen Po-Hung, Yenokyan Karine, Fojo Anthony T, Hutton Heidi E, Lesko Catherine R, McCaul Mary E, Yang Cui, Cachay Edward R, Crane Heidi M, Jacobson Jeffrey M, Kim H Nina, Kitahata Mari M, Mayer Kenneth H, Moore Richard D, Napravnik Sonia, Saag Michael, Lau Bryan, Chander Geetanjali

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Direct-acting antivirals (DAA) are highly effective against hepatitis C virus (HCV) infection among persons with human immunodeficiency virus (PWH). However, alcohol use post-DAA treatment poses a continued threat to the liver. Whether the focus on liver health alone during HCV treatment can impact alcohol consumption is unclear. Therefore, we examined the change in alcohol use among HCV-coinfected PWH who received DAA therapy by non-addiction medical providers.

METHODS

In our longitudinal clinical cohort study, we identified HCV-coinfected PWH who received interferon-free DAA therapy between January 2014 and June 2019 in the Centers for AIDS Research Network of Integrated Clinical Systems. The Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) was the alcohol screening instrument. We used mixed-effects logistic regression models to estimate the longitudinal change in alcohol use upon DAA therapy.

RESULTS

Among 738 HCV-coinfected PWH, 339 (46 %) reported any alcohol use at the end of HCV treatment, including 113 (15 %) with high-risk use (i.e., AUDIT-C ≥3 for women, ≥4 for men). Concurrently, 280 (38 %) PWH noted active drug use, and 357 (48 %) were currently smoking. We observed no changes in the odds of any alcohol or high-risk alcohol use over time with DAA therapy. Findings were similar in the PWH subgroup with a history of alcohol use before DAA treatment.

CONCLUSIONS

For PWH with HCV, alcohol use did not change following interferon-free DAA treatment by non-addiction medical providers. Thus, clinicians should consider integrating targeted alcohol use interventions into HCV care to motivate reduced alcohol consumption and safeguard future liver health.

Для цитирования: Chen Po-Hung, Yenokyan Karine, Fojo Anthony T, Hutton Heidi E, Lesko Catherine R, McCaul Mary E, Yang Cui, Cachay Edward R, Crane Heidi M, Jacobson Jeffrey M, Kim H Nina, Kitahata Mari M, Mayer Kenneth H, Moore Richard D, Napravnik Sonia, Saag Michael, Lau Bryan, Chander Geetanjali. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.. Drug and alcohol dependence. 2022. DOI: 10.1016/j.drugalcdep.2022.109673.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.